{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=30", "query": { "intervention": "combined treatment", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 13961, "total_pages": 1397, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T20:18:03.463Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00100789", "title": "S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "gemcitabine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2005-01", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 123, "location_summary": "Anniston, Alabama • Mobile, Alabama • Aurora, Colorado + 81 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Montrose", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100789" }, { "nct_id": "NCT05911360", "title": "A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "DTG/3TC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 205, "start_date": "2023-07-07", "completion_date": "2026-02-09", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05911360" }, { "nct_id": "NCT00061360", "title": "Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia" ], "interventions": [ { "name": "ATG+Rapamune+cyclosporine", "type": "DRUG" }, { "name": "ATG+cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "2 Years to 110 Years" }, "enrollment_count": 77, "start_date": "2003-06-26", "completion_date": "2015-09-08", "has_results": false, "last_update_posted_date": "2021-06-30", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061360" }, { "nct_id": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "NeoTCR-P1 adoptive cell therapy", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PACT Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-07-03", "completion_date": "2022-08-12", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970382" }, { "nct_id": "NCT02912559", "title": "Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colon Adenocarcinoma", "DNA Repair Disorder", "Lynch Syndrome", "Stage III Colon Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 712, "start_date": "2017-10-16", "completion_date": "2026-12-18", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 1026, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02912559" }, { "nct_id": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Gastric Cancer", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "Advanced Solid Tumors", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreatic Cancer", "Melanoma" ], "interventions": [ { "name": "FATE-NK100", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-01-18", "completion_date": "2020-12-15", "has_results": false, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03319459" }, { "nct_id": "NCT03564496", "title": "Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "tDCS Administration during MRI", "type": "DEVICE" }, { "name": "Remotely-supervised Daily tDCS Administration", "type": "DEVICE" }, { "name": "Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 73, "start_date": "2018-07-09", "completion_date": "2021-09-29", "has_results": true, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564496" }, { "nct_id": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papillomavirus-16 Positive", "Human Papillomavirus-18 Positive", "Metastatic Malignant Neoplasm", "Recurrent Anal Canal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Penile Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Refractory Malignant Neoplasm", "Stage IV Anal Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8" ], "interventions": [ { "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-11-14", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439085" }, { "nct_id": "NCT00805285", "title": "The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammatory Bowel Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Combination Oral Budesonide and Rectal Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-10", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2019-12-04", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805285" }, { "nct_id": "NCT00006291", "title": "Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": null, "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-15T20:18:03.463Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006291" } ] }